Working… Menu
Trial record 54 of 318 for:    FLUTICASONE AND SALMETEROL

Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01393145
Recruitment Status : Withdrawn
First Posted : July 13, 2011
Last Update Posted : February 15, 2017
Information provided by (Responsible Party):
Ache Laboratorios Farmaceuticos S.A.

Brief Summary:
A study multicenter, phase III, randomized, open label study to evaluate the efficacy and safety of a fixed-dose combination of formoterol/fluticasone and salmeterol/fluticasone in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) that will enroll 336 subjects aged ≥ 40 years, smokers or former smokers, diagnosed with chronic obstructive pulmonary disease, classified as moderate chronic obstructive pulmonary disease or severe according to GOLD spirometric classification. The subjects will be allocated in 2 parallel groups and will receive the medicines of study, according of the randomization during a 24-week.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease COPD Drug: Combination Fluticasone /Formoterol 12/250 μg Drug: Seretide Diskus (salmeterol/fluticasone) 50/250 μg Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter, Phase III, Randomized, Open Label Study to Evaluate the Efficacy and Safety of a Fixed-dose Combination of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD).
Study Start Date : August 2011
Estimated Primary Completion Date : August 2012
Estimated Study Completion Date : August 2012

Arm Intervention/treatment
Experimental: Group 1 Drug: Combination Fluticasone /Formoterol 12/250 μg
Capsules containing Fumarate formoterol 12 µg + fluticasone propionate 250 µg dry powder for inhalation with aerocaps®

Active Comparator: Group 2 Drug: Seretide Diskus (salmeterol/fluticasone) 50/250 μg
Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses

Primary Outcome Measures :
  1. Changes in pre-bronchodilator forced expiratory volume in first second (FEV1) [ Time Frame: Comparative between baseline and week 24 ]
    Changes of lung function parameter

Secondary Outcome Measures :
  1. Changes in forced expiratory volume in first second, without bronchodilator [ Time Frame: Week 0, 8, 16 and 24 ]
    Changes of lung function parameter

  2. Safety descriptive about occurence of adverse events, evaluation of results of clinical/physical examination and laboratory tests results [ Time Frame: From baseline to week 24 ]
    Collection of safety data throughout the whole study period

  3. Changes in COPD Assessment Test (CAT) [ Time Frame: Week 0, 8, 16 and 24 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age ≥ 40 years;
  2. Chronic obstructive pulmonary disease classified as moderate or severe according to GOLD guidelines (Global Initiative for Chronic Obstructive Lung Disease), with post-bronchodilator FEV1/FVC <0.70, and post-bronchodilator FEV1 <80% and ≥ 30% predicted;
  3. Understanding and capacity to give written consent;
  4. Smoker or ex-smoker of ≥ 10 pack-years [number of pack-years = number of daily cigarettes / 20 x number of years of smoking (eg t10 pack-years is equal to 20 cigarettes / day for 10 years, or 10 cigarettes per day within 20 years)].
  5. Ability to fill out the patient's Diary
  6. Ability to fill out the MRC dyspnea scale and questionnaires CAT and CDLM.

Exclusion Criteria:

  1. Presence of clinically associate morbidities manifested according to the investigator that would interfere in the evaluation, for example: diabetes mellitus, congestive heart failure, coronary heart disease, chronic renal failure, liver failure, arrhythmia, hypothyroidism or hyperthyroidism;
  2. Presence of neuro-psychiatric disorders of any kind;
  3. Presence of mental retardation of any etiology;
  4. Presence of pulmonary malformations, bronchiectasis, cystic fibrosis, bronchopulmonary hemosiderosis, ciliary dyskinesia, alveolitis, hypersensitivity, pulmonary vasculitis, sarcoidosis, tuberculosis or other lung diseases that might interfere with study assessments, as the investigator's discretion;
  5. Subjects using immunosuppressive therapy, immunomodulatory agents, chemotherapy for allergy or any other immunotherapy;
  6. Subjects using xanthine or acebrophylline;
  7. Use within two months preceding the screening visit (V-2) of: anti-leukotrienes, immunoglobulins (including omalizumab), beta blockers, digitalis, itraconazole, amiodarone, antidepressants, monoamine oxidase inhibitors, tricyclic antidepressants, rifampin, oral contraceptives and coumarin ;
  8. Current diagnosis of asthma;
  9. Symptomatic coronary insufficiency;
  10. Surgery for lung volume reduction and / or lung transplantation;
  11. Need for long-term oxygen therapy (defined as the need for oxygen therapy ≥ 12 hours / day);
  12. Pregnant or test β-HCG serum positive;
  13. Lactating women;
  14. Subject who uses more than 2 alcohol drinks a day or> 14 drinks a week;
  15. Subject with a history of malignancy or ≤ 5 years> 5 years, but without documentation of remission / cure.
  16. Illiterate or individuals who have limitation in understanding the use of devices as well as an inability to understand the questionnaires and diary that will be applied; Exception: subject illiterate, but capable of understanding regarding the use of the device, the questionnaires and diaries of the study and make available for relatives who can fill the diary study.
  17. History of hypersensitivity to study drugs and rescue;
  18. Any other disease or therapy that in the opinion of the investigator would jeopardize the subject or interfere with the objective of the study;
  19. Subject with a history of ineffectiveness of formoterol fumarate, to fluticasone or salmeterol xinafoate;
  20. Subject who participated in another study within 1 (one) year;
  21. Pregnant women or those with positive serum β-HCG;
  22. Radiological change is not compatible with COPD;
  23. Clinically significant ECG changes, as reported by the investigator;
  24. Any other disease, therapy or laboratory abnormality which in the opinion of the investigator would jeopardize the subject or interfere with the objective of the study;
  25. Use of medications prescribed in the exclusion criteria for visit V -2.
  26. Subjects who had an exacerbation during the standardization that required systemic corticosteroids and / or antibiotics or hospitalization will not be eligible for randomization.
  27. Use of oral corticosteroids, anti-leukotrienes, immunoglobulins (including omalizumab), beta blockers, digitalis, amiodarone, itraconazole, antidepressants, monoamine oxidase inhibitors and tricyclic antidepressants during the period of standardization;
  28. Any other disease or therapy that in the opinion of the investigator would jeopardize the subject or interfere with the objective of the study

Layout table for additonal information
Responsible Party: Ache Laboratorios Farmaceuticos S.A. Identifier: NCT01393145     History of Changes
Other Study ID Numbers: ACH-LLN-03(06/10)
First Posted: July 13, 2011    Key Record Dates
Last Update Posted: February 15, 2017
Last Verified: February 2017
Keywords provided by Ache Laboratorios Farmaceuticos S.A.:
Chronic obstructive pulmonary disease (COPD)
Additional relevant MeSH terms:
Layout table for MeSH terms
Salmeterol Xinafoate
Fluticasone-Salmeterol Drug Combination
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Formoterol Fumarate
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists